Abstract
Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 499-502 |
| Number of pages | 4 |
| Journal | Transplantation Proceedings |
| Volume | 41 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2009 |
| Externally published | Yes |
ASJC Scopus subject areas
- Surgery
- Transplantation
Fingerprint Dive into the research topics of 'Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?'. Together they form a unique fingerprint.
Cite this
Schneeberger, S., Landin, L., Kaufmann, C., Gorantla, V. S., Brandacher, G., Cavadas, P., Lee, W. P. A., Breidenbach, W. C., & Margreiter, R. (2009). Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation? Transplantation Proceedings, 41(2), 499-502. https://doi.org/10.1016/j.transproceed.2009.01.018